The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in ViroPharma Incorporated of Class Action Lawsuit and the Deadline of July 17, 2012 to Seek a Lead Plaintiff Position

NEW YORK, NY--(Marketwire - Jun 4, 2012) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of investors who purchased ViroPharma Incorporated ("ViroPharma" or the "Company") (NASDAQ: VPHM) stock between December 14, 2011 and April 9, 2012.

For more information, click here: http://zlk.9nl.com/viropharma. There is no cost or obligation to you.

The complaint alleges that during the Class Period ViroPharma made false and/or misleading statements, or failed to disclose material information regarding its drug Vancocin. On December 14, 2011, the Company stated that the Food & Drug Administration approved a supplemental drug application, and that Vancocin would receive market exclusivity for three years. Then on April 10, 2012, the Company revealed that the drug would not qualify for exclusivity, and that three applications for generic versions of the drug had received approval. The Company also acknowledged that it was under investigation by the Federal Trade Commission in relation to possible "unfair methods of competition" relating to the drug. Upon this news shares of ViroPharma fell more than 20 percent.

If you suffered a loss in ViroPharma you have until July 17, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/viropharma.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.